MPT0G211

MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM) . MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities[1][2][3].

Product Specifications

CAS Number

[2151853-97-1]

UNSPSC

12352005

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mpt0g211.html

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NO)C1=CC=C(CNC2=C3N=CC=CC3=CC=C2)C=C1

Molecular Formula

C17H15N3O2

Molecular Weight

293.32

References & Citations

[1]Fan SJ, Huang FI, et al. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis. 2018;9 (6) :655. Published 2018 May 29.|[2]Hsieh YL, et al. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res. 2019;1866 (6) :992-1003.|[3]Tu HJ, et al. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clin Epigenetics. 2018;10 (1) :162. Published 2018 Dec 29.